DOSAGE & ADMINISTRATION: ABRAXANE + CARBOPLATIN

- Administer ABRAXANE intravenously at a dose of 100 mg/m2 over 30 minutes on a weekly schedule on Days 1, 8, and 15 of each 21-day cycle
- Administer carboplatin intravenously on Day 1 of each 21-day cycle immediately after completion of ABRAXANE administration
ABRAXANE is administered generally without the need for steroid pretreatment
- Premedication may be needed in patients who have had a prior hypersensitivity reaction to ABRAXANE
- Severe hypersensitivity reactions with fatal outcome have been reported with ABRAXANE. Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be rechallenged with this drug
- Patients with a previous history of hypersensitivity to other taxanes should be closely monitored during initiation of ABRAXANE therapy
- Premedication may be needed in patients who have had a prior hypersensitivity reaction to ABRAXANE
- Severe hypersensitivity reactions with fatal outcome have been reported with ABRAXANE. Patients who experience a severe hypersensitivity reaction to ABRAXANE should not be rechallenged with this drug
- Patients with a previous history of hypersensitivity to other taxanes should be closely monitored during initiation of ABRAXANE therapy
- Duration and Dosing in the Phase III Trial
MEDIAN NUMBER OF TREATMENT CYCLES IN THE PHASE III PIVOTAL TRIAL OF ABRAXANE + CARBOPLATIN
MEDIAN NUMBER OF TREATMENT CYCLES IN THE PHASE III PIVOTAL TRIAL OF ABRAXANE + CARBOPLATIN
Patients in the study were treated until disease progression or development of unacceptable toxicity.DOSE ADJUSTMENTS
OBSERVED IN THE PHASE III PIVOTAL TRIALDOSE ADJUSTMENTS
OBSERVED IN THE PHASE III PIVOTAL TRIALAdverse reactions were assessed in 514 patients treated with ABRAXANE + carboplatin - Dose ModificationsPLEASE SELECT A DOSE MODIFICATION BELOW:
- Hepatic
START WITH THE RIGHT DOSE OF ABRAXANE IN PATIENTS
WITH HEPATIC IMPAIRMENTSTART WITH THE RIGHT DOSE OF ABRAXANE IN PATIENTS
WITH HEPATIC IMPAIRMENTRecommendations for starting dose in patients with hepatic impairmentSGOT (AST) LEVELS
<10 x ULNANDBILIRUBIN LEVELS
>ULN TO ≤1.5 x ULNSGOT (AST) LEVELS
≤10 x ULNANDBILIRUBIN LEVELS
>ULN TO ≤1.5 x ULNSGOT (AST) LEVELS ≤10 x ULNANDBILIRUBIN LEVELS >1.5 TO ≤3 x ULNSGOT (AST) LEVELS
<10 x ULNANDBILIRUBIN LEVELS
>1.5 TO ≤3 x ULNSGOT (AST) LEVELS <10 x ULNANDBILIRUBIN LEVELS >3 TO ≤5 x ULNSGOT (AST) LEVELS
<10 x ULNANDBILIRUBIN LEVELS
>3 TO ≤5 x ULNSGOT (AST) LEVELS
>10 x ULNORBILIRUBIN LEVELS >5 x ULNSGOT (AST) LEVELS
>10 x ULNORBILIRUBIN LEVELS
>5 x ULNMild
- No dose adjustment is necessary for patients with mild hepatic impairment
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
Moderate
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
Severe
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
Very Severe
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
AST=aspartate aminotransferase; SGOT=serum glutamic-oxaloacetic transaminase; ULN=upper limit of normal.ABRAXANE dose
ILLUSTRATIVE PURPOSES ONLY
- aA dose increase to 100 mg/m2 in subsequent courses should be considered if the patient tolerates the reduced dose for 2 cycles.
- Neutropenia
DOSING FOR YOUR PATIENTS
WHO EXPERIENCE HEMATOLOGIC TOXICITIESDOSING FOR YOUR PATIENTS
WHO EXPERIENCE HEMATOLOGIC TOXICITIESRecommendations for permanent dose modification in NSCLC patients with neutropeniaMAKE A SELECTION:
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Nadir ANC <500 cells/mm3 with neutropenic fever >38 °C
OR- Delay of next cycle due to persistent neutropeniaa
(nadir ANC <1500 cells/mm3)
OR- Nadir ANC <500 cells/mm3 for >1 week
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Nadir ANC <500 cells/mm3 with neutropenic fever >38 °C
OR- Delay of next cycle due to persistent neutropeniaa
(nadir ANC <1500 cells/mm3)
OR- Nadir ANC <500 cells/mm3 for >1 week
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Nadir ANC <500 cells/mm3 with neutropenic fever >38 °C
OR- Delay of next cycle due to persistent neutropeniaa
(nadir ANC <1500 cells/mm3)
OR- Nadir ANC <500 cells/mm3 for >1 week
ILLUSTRATIVE PURPOSES ONLY
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced
Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced
Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grade 3-4 neutropenia
- aMore than 7-day delay of scheduled Day 1 dose of next cycle.
- Thrombocytopenia
DOSING FOR YOUR PATIENTS
WHO EXPERIENCE HEMATOLOGIC TOXICITIESDOSING FOR YOUR PATIENTS
WHO EXPERIENCE HEMATOLOGIC TOXICITIESRecommendations for permanent dose modification in NSCLC patients with thrombocytopeniaMAKE A SELECTION:
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Prior to permanent dose reduction, withhold treatment until platelet count recovery to ≥100,000 cells/mm3 on Day 1 or ≥50,000 cells/mm3 on Days 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 68% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 thrombocytopenia; 18% experienced Grades 3-4 thrombocytopenia
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Prior to permanent dose reduction, withhold treatment until platelet count recovery to ≥100,000 cells/mm3 on Day 1 or ≥50,000 cells/mm3 on Days 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 68% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 thrombocytopenia; 18% experienced Grades 3-4 thrombocytopenia
Nadir platelets <50,000 cells/mm3
ILLUSTRATIVE PURPOSES ONLY
- Neurologic
DOSING FOR YOUR PATIENTS
WHO EXPERIENCE NEUROLOGIC TOXICITIESDOSING FOR YOUR PATIENTS
WHO EXPERIENCE NEUROLOGIC TOXICITIESRecommendations for permanent dose modification in NSCLC patients with neurologic toxicityMAKE A SELECTION:
- For Grades 3-4 peripheral neuropathy, withhold treatment until resolution to ≤ Grade 1
- Treatment may be resumed at the next lower dose level in subsequent cycles according to the dose reduction guidelines for neurologic toxicity
- In the Phase III ABRAXANE NSCLC clinical trial, 48% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 peripheral neuropathy; 3% experienced Grades 3-4 peripheral neuropathy; no Grade 4 peripheral neuropathy was seen in the ABRAXANE + carboplatin arm
- For Grades 3-4 peripheral neuropathy, withhold treatment until resolution to ≤ Grade 1
- Treatment may be resumed at the next lower dose level in subsequent cycles according to the dose reduction guidelines for neurologic toxicity
- In the Phase III ABRAXANE NSCLC clinical trial, 48% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 peripheral neuropathy; 3% experienced Grades 3-4 peripheral neuropathy; no Grade 4 peripheral neuropathy was seen in the ABRAXANE + carboplatin arm
- For Grades 3-4 peripheral neuropathy, withhold treatment until resolution to ≤ Grade 1
- Treatment may be resumed at the next lower dose level in subsequent cycles according to the dose reduction guidelines for neurologic toxicity
- In the Phase III ABRAXANE NSCLC clinical trial, 48% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 peripheral neuropathy; 3% experienced Grades 3-4 peripheral neuropathy; no Grade 4 peripheral neuropathy was seen in the ABRAXANE + carboplatin arm
Severe sensory neuropathy
(Grade 3 or 4)ILLUSTRATIVE PURPOSES ONLY
Recommendations for starting dose in patients with hepatic impairmentSGOT (AST) LEVELS
<10 x ULNANDBILIRUBIN LEVELS
>ULN TO ≤1.5 x ULNSGOT (AST) LEVELS
≤10 x ULNANDBILIRUBIN LEVELS
>ULN TO ≤1.5 x ULNSGOT (AST) LEVELS ≤10 x ULNANDBILIRUBIN LEVELS >1.5 TO ≤3 x ULNSGOT (AST) LEVELS
<10 x ULNANDBILIRUBIN LEVELS
>1.5 TO ≤3 x ULNSGOT (AST) LEVELS <10 x ULNANDBILIRUBIN LEVELS >3 TO ≤5 x ULNSGOT (AST) LEVELS
<10 x ULNANDBILIRUBIN LEVELS
>3 TO ≤5 x ULNSGOT (AST) LEVELS
>10 x ULNORBILIRUBIN LEVELS >5 x ULNSGOT (AST) LEVELS
>10 x ULNORBILIRUBIN LEVELS
>5 x ULNMild
- No dose adjustment is necessary for patients with mild hepatic impairment
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
Moderate
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
Severe
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
- Dosage recommendations are for the first course of therapy. The need for further dose adjustments in subsequent courses should be based on individual tolerance
Very Severe
- Do not administer ABRAXANE to patients with total bilirubin >5 x ULN or AST >10 x ULN
- Patients with bilirubin levels above the ULN were excluded from the clinical trial for lung cancer
AST=aspartate aminotransferase; SGOT=serum glutamic-oxaloacetic transaminase; ULN=upper limit of normal.ABRAXANE dose
ILLUSTRATIVE PURPOSES ONLY
- aA dose increase to 100 mg/m2 in subsequent courses should be considered if the patient tolerates the reduced dose for 2 cycles.
Recommendations for permanent dose modification in NSCLC patients with neutropeniaMAKE A SELECTION:
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Nadir ANC <500 cells/mm3 with neutropenic fever >38 °C
OR- Delay of next cycle due to persistent neutropeniaa
(nadir ANC <1500 cells/mm3)
OR- Nadir ANC <500 cells/mm3 for >1 week
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Nadir ANC <500 cells/mm3 with neutropenic fever >38 °C
OR- Delay of next cycle due to persistent neutropeniaa
(nadir ANC <1500 cells/mm3)
OR- Nadir ANC <500 cells/mm3 for >1 week
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Nadir ANC <500 cells/mm3 with neutropenic fever >38 °C
OR- Delay of next cycle due to persistent neutropeniaa
(nadir ANC <1500 cells/mm3)
OR- Nadir ANC <500 cells/mm3 for >1 week
ILLUSTRATIVE PURPOSES ONLY
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced
Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced
Grades 3-4 neutropenia
- Prior to permanent dose reduction, withhold treatment until ANC recovery to ≥1500 cells/mm3 on Day 1 or ≥500 cells/mm3 on Day 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 85% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 neutropenia; 47% experienced Grade 3-4 neutropenia
- aMore than 7-day delay of scheduled Day 1 dose of next cycle.
Recommendations for permanent dose modification in NSCLC patients with thrombocytopeniaMAKE A SELECTION:
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Prior to permanent dose reduction, withhold treatment until platelet count recovery to ≥100,000 cells/mm3 on Day 1 or ≥50,000 cells/mm3 on Days 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 68% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 thrombocytopenia; 18% experienced Grades 3-4 thrombocytopenia
- Do not administer ABRAXANE on Day 1 of a cycle until absolute neutrophil count (ANC) is at least 1500 cells/mm3 and platelet count is at least 100,000 cells/mm3
- Prior to permanent dose reduction, withhold treatment until platelet count recovery to ≥100,000 cells/mm3 on Day 1 or ≥50,000 cells/mm3 on Days 8 or 15 of the cycle
- Monitor for myelotoxicity by performing complete blood cell counts frequently, including prior to dosing on Days 1, 8, and 15
- In the Phase III ABRAXANE NSCLC clinical trial, 68% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 thrombocytopenia; 18% experienced Grades 3-4 thrombocytopenia
Nadir platelets <50,000 cells/mm3
ILLUSTRATIVE PURPOSES ONLY
Recommendations for permanent dose modification in NSCLC patients with neurologic toxicityMAKE A SELECTION:
- For Grades 3-4 peripheral neuropathy, withhold treatment until resolution to ≤ Grade 1
- Treatment may be resumed at the next lower dose level in subsequent cycles according to the dose reduction guidelines for neurologic toxicity
- In the Phase III ABRAXANE NSCLC clinical trial, 48% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 peripheral neuropathy; 3% experienced Grades 3-4 peripheral neuropathy; no Grade 4 peripheral neuropathy was seen in the ABRAXANE + carboplatin arm
- For Grades 3-4 peripheral neuropathy, withhold treatment until resolution to ≤ Grade 1
- Treatment may be resumed at the next lower dose level in subsequent cycles according to the dose reduction guidelines for neurologic toxicity
- In the Phase III ABRAXANE NSCLC clinical trial, 48% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 peripheral neuropathy; 3% experienced Grades 3-4 peripheral neuropathy; no Grade 4 peripheral neuropathy was seen in the ABRAXANE + carboplatin arm
- For Grades 3-4 peripheral neuropathy, withhold treatment until resolution to ≤ Grade 1
- Treatment may be resumed at the next lower dose level in subsequent cycles according to the dose reduction guidelines for neurologic toxicity
- In the Phase III ABRAXANE NSCLC clinical trial, 48% of patients treated with ABRAXANE (100 mg/m2 weekly) + carboplatin experienced Grades 1-4 peripheral neuropathy; 3% experienced Grades 3-4 peripheral neuropathy; no Grade 4 peripheral neuropathy was seen in the ABRAXANE + carboplatin arm
Severe sensory neuropathy
(Grade 3 or 4)ILLUSTRATIVE PURPOSES ONLY
THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY. - Hepatic
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Celgene Corporation
The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.
Please see Important Safety Information and Prescribing Information, including Boxed WARNING.
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
YOU ARE NOW LEAVING www.abraxanepro.com
Additional Information for Readers Provided by Bristol Myers Squibb
The clinical trial described in this article served as the
basis for the approval for ABRAXANE for Injectable Suspension.
The analyses contained in the article may differ from those in the package insert for ABRAXANE.
Please see Important Safety Information and Prescribing Information, including Boxed WARNING.
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
YOU ARE NOW LEAVING www.abraxanepro.com
Click “OK” to proceed or “CANCEL” to return to
www.abraxanepro.com
FOR HEALTHCARE PROFESSIONALS
The information contained in this section of www.abraxanepro.com is technical in nature and is intended for US healthcare professionals only.
If you are not a US healthcare professional, click “CANCEL” below to return to the patient and caregiver section of the site. Click “OK” if you are a healthcare professional.
OK CANCELFOR HEALTHCARE PROFESSIONALS
The information contained in this section of www.abraxanepro.com is technical in nature and is intended for US healthcare professionals only.
If you are not a US healthcare professional, click “CANCEL” below to return to the patient and caregiver section of the site. Click “OK” if you are a healthcare professional.
OK CANCEL